Table 2.
Clinical, Histopathological and Protein Expression in EBV Positive (EBNA1) Cases (n=50)
| EBV positive % (n) |
EBV negative % (n) |
P | |
|---|---|---|---|
| Age | |||
| ≤45 years old (20) | 28 (14) | 27.3 (6) | 0.94 |
| >45 years old (52) | 72 (36) | 72.7 (16) | |
| Grade | |||
| I (15) | 27.3 (12) | 15 (3) | 0.22 |
| II (17) | 22.7 (10) | 35 (7) | 0.30 |
| III (32) | 50 (22) | 50 (10) | 1.00 |
| Lymph node status | |||
| Positive (33) | 75 (24) | 75 (9) | 0.64 |
| Negative (11) | 25 (8) | 25 (3) | |
| Molecular markers | |||
| ER+ (52) | 72 (36) | 72.7 (16) | 0.94 |
| PR+ (41) | 58 (29) | 54.5 (12) | 0.78 |
| Her2+ (10) | 14 (07) | 13.6 (03) | 0.64 |
| Ki67+ (50) | 68 (34) | 72.7 (16) | 0.68 |
| P53+ (23) | 34 (17) | 27.3 (06) | 0.57 |
| Molecular subtypes | |||
| Luminal A (23) | 36 (18) | 31.8 (7) | |
| Luminal B (24) | 30 (15) | 31.8 (7) | 0.082 |
| Her2 (10) | 14 (7) | 13.6 (3) | 0.96 |
| Basal like (04) | 06 (3) | 4.5 (1) | 0.80 |
| Normal like (11) | 14 (7) | 18.2 (4) | 0.64 |
| Triple negative (15) | 20 (10) | 22.7 (05) | 0.79 |
ER, estrogen receptor; PR, progesterone receptor.